1,048,518 Insmed, Inc. $INSM Shares Bought by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Insmed stake by 480.4% in the third quarter, purchasing 1.05 million additional shares and bringing its holdings to 1.27 million shares valued at approximately $144.6 million.
• Insmed reported quarterly revenue of $425.5 million, up 296.1% year over year, and an adjusted loss of $0.06 per share that surpassed analyst expectations. However, the company remains unprofitable, with analysts forecasting a full-year loss of $1.72 per share.
• Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and a $200.30 price target versus the stock’s recent $99.21 price. This optimism contrasts with insider selling by the COO and a director, who collectively sold about $35.1 million in shares.

Assenagon Asset Management S.A. grew its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 480.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,266,788 shares of the biopharmaceutical company's stock after acquiring an additional 1,048,518 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.58% of Insmed worth $144,591,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Sei Investments Co. increased its stake in Insmed by 56.8% during the first quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company's stock valued at $228,239,000 after purchasing an additional 505,624 shares during the last quarter. Castle Hook Partners LP lifted its holdings in Insmed by 14.9% in the fourth quarter. Castle Hook Partners LP now owns 1,253,568 shares of the biopharmaceutical company's stock worth $218,171,000 after acquiring an additional 162,163 shares during the last quarter. Pictet Asset Management Holding SA lifted its holdings in Insmed by 14.9% in the first quarter. Pictet Asset Management Holding SA now owns 1,102,248 shares of the biopharmaceutical company's stock worth $178,659,000 after acquiring an additional 143,285 shares during the last quarter. NWI Management LP boosted its stake in Insmed by 2.6% in the first quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company's stock valued at $165,809,000 after acquiring an additional 25,540 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in Insmed by 18.8% in the first quarter. Principal Financial Group Inc. now owns 916,464 shares of the biopharmaceutical company's stock valued at $149,860,000 after acquiring an additional 145,106 shares during the period.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $99.21 on Friday. The firm's 50 day moving average is $119.47 and its two-hundred day moving average is $118.42. The firm has a market capitalization of $21.67 billion, a P/E ratio of -24.14 and a beta of 0.83. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74. Insmed, Inc. has a 52 week low of $90.39 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.61. The business had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The business's revenue was up 296.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.70) earnings per share. Analysts anticipate that Insmed, Inc. will post -1.72 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on INSM. UBS Group reaffirmed a "buy" rating on shares of Insmed in a report on Thursday, October 8th. Evercore reissued an "outperform" rating and issued a $170.00 price target on shares of Insmed in a report on Friday, August 7th. Cantor Fitzgerald reissued an "overweight" rating and issued a $235.00 price target on shares of Insmed in a report on Tuesday, July 28th. BMO Capital Markets restated an "outperform" rating on shares of Insmed in a research report on Tuesday, October 6th. Finally, Morgan Stanley restated an "overweight" rating and set a $218.00 price objective on shares of Insmed in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $200.30.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: HC Wainwright raised its 2026 EPS forecast to a loss of $1.26 per share from a projected loss of $1.86, and improved its quarterly estimates for the third and fourth quarters. The firm reiterated its Buy rating and $220 price target, signaling expectations for better-than-previously-anticipated financial performance. HC Wainwright raises Insmed earnings estimates
• Positive Sentiment: Insmed is highlighting its global Phase 3 PALM program for treprostinil palmitil inhalation powder (TPIP) at CHEST 2026. The program includes four pivotal studies spanning pulmonary arterial hypertension, interstitial lung disease, progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, broadening the potential commercial opportunity for TPIP. Insmed presents PALM Phase 3 program at CHEST 2026
• Positive Sentiment: New respiratory data from the TPIP, ASPEN and ENCORE programs will be presented at CHEST 2026 and IDWeek 2026. The disclosures could strengthen confidence in Insmed’s pipeline, including TPIP’s potential in PAH and PH-ILD and treatment strategies for MAC lung disease. Insmed respiratory data presentations
• Neutral Sentiment: UBS maintained its $172 price target for Insmed. The target remains substantially above the recent trading level, but the lack of an upgrade or target increase makes this more of a reaffirmation than a new catalyst. UBS maintains Insmed price target

Insider Buying and Selling at Insmed

In other news, COO Roger Adsett sold 239,850 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the transaction, the chief operating officer directly owned 98,744 shares of the company's stock, valued at approximately $13,159,612.88. This trade represents a 70.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Brennan sold 25,000 shares of the firm's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the transaction, the director directly owned 39,238 shares in the company, valued at approximately $4,865,512. The trade was a 38.92% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company's research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed's principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.